Boston-based healthcare venture capital firm Omega Funds closed its seventh and largest fund with $650 million in capital commitments, handily beating its $500 million target on the back of strong support from new as well as existing limited partners. Omega Fund VII also significantly outpaced its predecessor, as Fund VI closed with $438 million in December 2019.
Omega said Fund VII is "stage-agnostic," meaning its investments will run the gamut from seed founding to early venture rounds and later-stage financings, albeit with a focus on companies in the U.S. and Europe.
Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Annual subscriptions get you the most bang for your buck, including access to Alternatives Watch Research articles and out Annual Investor Compendium.
Monthly subscriptions and discounted corporate plans for up to 100 members also available.